J&J posts a sol­id round of pos­i­tive ear­ly da­ta for their BC­MA/CD3 bis­pe­cif­ic teclis­tam­ab, high­light­ing block­buster ex­pec­ta­tions

J&J’s on­col­o­gy R&D team has post­ed promis­ing ear­ly da­ta on one of its block­buster drug can­di­dates in the pipeline.

JNJ-7957, their BC­MA/CD3 bis­pe­cif­ic now called …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER